PaxMedica Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Howard Weisman

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	45.5%
Dienstverband CEO	4.7yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

PaxMedica to debut on Nasdaq after pricing scaled-down $8.1M IPO

Aug 26

Analyse CEO-vergoeding

Hoe is Howard Weisman's beloning veranderd ten opzichte van PaxMedica's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	n/a	n/a	-US$18m
Dec 31 2023	US$1m	US$478k	-US$18m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$4m	US$400k	-US$15m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	US$4m
Mar 31 2022	n/a	n/a	-US$2m
Dec 31 2021	US$558k	US$400k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 1.05M ) Howard } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 642.50K ).

Compensatie versus inkomsten: De vergoeding van Howard is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Howard Weisman (65 yo)

4.7yrs

Tenure

US$1,050,224

Compensatie

Mr. Howard J. Weisman has been the Chief Executive Officer and Director of PaxMedica Inc. since March 2020 and serves as its Chairman since August 21, 2023. Prior to joining PaxMedica, from September 2016...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Howard Weisman	CEO & Chairman	4.7yrs	US$1.05m	0.31% $ 3.4k
Charles Casamento	Lead Independent Director	2.1yrs	US$98.83k	0.0013% $ 14.7
Stefan K. Schwabe	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens
Reymundo Lozano	Member of Advisory Board	no data	geen gegevens	geen gegevens
Karen LaRochelle	Independent Director	4.3yrs	US$83.31k	0.020% $ 218.5
Michael Aman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Zachary Rome	Director	5.7yrs	US$358.28k	0.091% $ 992.7
Constance Smith-Hicks	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Alice Mao	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Coelho	Independent Director	2.5yrs	US$79.47k	0.039% $ 427.2
Veronica Martinez Cerdeno	Member of Advisory Board	no data	geen gegevens	geen gegevens
Robert Naviaux	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PXMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

PaxMedica Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

PaxMedica, Inc., Annual General Meeting, May 23, 2024

PaxMedica, Inc. Announces Executive Changes

PaxMedica, Inc. Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

PaxMedica, Inc. Appoints Charles J. Casamento to its Board of Directors

Less than half of directors are independent

Less than half of directors are independent

Recent updates

PaxMedica, Inc. announced delayed 10-Q filing

PaxMedica, Inc. Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

PaxMedica, Inc. announced delayed 10-Q filing

PaxMedica, Inc. Receives Non-Compliance Letter Regarding Minimum Shareholders Equity

Nasdaq Hearings Panel Determines to Delist PaxMedica's Common Stock and Trading of its Securities to be Suspended at the Open of Trading on May 2, 2024

PaxMedica, Inc., Annual General Meeting, May 23, 2024

PaxMedica, Inc. Achieves Key Milestone in the Development of Pax-101 and Provides Update on Potential NDA Submission

New major risk - Share price stability

New major risk - Financial position

PaxMedica Receives Non-Compliance Notice From Nasdaq

PaxMedica, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

PaxMedica, Inc. announced delayed 10-Q filing

PaxMedica, Inc. has filed a Follow-on Equity Offering.

PaxMedica, Inc. (NasdaqCM:PXMD) acquired Certain Suramin Research Assets from Rediscovery Life Sciences AKI LLC.

Paxmedica, Inc. Holds Important Fda Type-B Meeting to Review Pax-101 Pivotal Trial Data

New major risk - Share price stability

PaxMedica Receives Decision from the Hearings Panel of Nasdaq Granting its Request for an Exception to Maintain its Listing on the Nasdaq Capital Market Notwithstanding its Failure to Regain Compliance with Nasdaq Listing Rule 5550(b)(2)

PaxMedica, Inc. Announces Executive Changes

PaxMedica Receives Written Notification from Nasdaq Regarding Non-Compliance with the Minimum Closing Bid Price Requirement

New major risk - Market cap size

PaxMedica, Inc. Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

PaxMedica, Inc. Submits Request to South African Health Products Regulatory Authority, Seeking Approval to Conduct Double-Blind, Placebo-Controlled Study, PAX-ASD-101

PaxMedica, Inc. announced that it has received $3.68 million in funding from The Lind Partners, LLC

PaxMedica, Inc. announced that it expects to receive $3.2 million in funding

PaxMedica Receives Non-Compliance Notice From Nasdaq

PaxMedica, Inc. announced that it expects to receive $20 million in funding from Lincoln Park Capital, LLC

PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission

PaxMedica, Inc. Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

PaxMedica, Inc. Appoints Charles J. Casamento to its Board of Directors

PaxMedica, Inc. announced delayed 10-Q filing

PaxMedica, Inc. has completed an IPO in the amount of $8.113634 million.

PaxMedica to debut on Nasdaq after pricing scaled-down $8.1M IPO

Less than half of directors are independent

Less than half of directors are independent

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd